ImmPACT Bio announces Kalthera merger

22 July 2021

Cancer-focused cell therapy company ImmPACT Bio has announced its merger with Californian biotech Kalthera.

At present, Kalthera is progressing a trial at the University of California, Los Angeles (UCLA) Jonsson Comprehensive Cancer Center with a pioneering bispecific CAR T-cell immunotherapy candidate targeting CD19/CD20.

"ImmPACT Bio is developing cutting-edge CAR T-cell platform technologies to address the key challenges for current cell therapies in oncology"Early results indicated the bispecific CAR T-cell candidate is safe and effective in patients with relapsed or refractory B-cell lymphoma. After a median follow up of up to nine months, six of the seven patients in the trial have ongoing complete remission.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK